A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

Phase 1 Completed 43 enrolled Novo Nordisk A/S

RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in the United States of America (USA). The aim of the trial is to evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog® in subjects with type 1 diabetes.

Timeline

Start: 2012-09
Primary completion: 2013-03
Completion: 2013-03

Outcome

Met primary endpoint

paper Faster aspart provided a statistically significantly greater glucose-lowering effect following the meal versus IAsp: PMID 28055230 ↗

paper P = 0.044 PMID 28055230 ↗

Publications

Results Bode BW, Johnson JA, Hyveled L, Tamer SC, Demissie M. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. Diabetes Technol Ther. 2017 Jan;19(1):25-33. doi: 10.1089/dia.2016.0350. Epub 2017 Jan 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Faster aspart	Unknown	—	Subcutaneous
Comparator	insulin aspart	Protein / enzyme biologic	—	Subcutaneous